8.
Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337: 762-769.
9.
Kael DK, Hebbel RP. Hypoxia/ reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest 2000; 106: 411-420.
10.
Ergul S, Brunson CY, Hutchinston J, et al. Vasoactive factors in sickle cell disease in vitro evidence for endothelin 1 mediated vasoconstriction. Am J Hematol 2004; 76: 245.
11.
Rother RP, Bell I, Hillmen P, et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanisms of human disease. JAMA 2005; 293: 1653-1662.
12.
Reter CD, Wang X, Tanus-Santos JE, et al. Cell free hemoglobin limits nitric oxide bioavailability in sickle cell disease. Nat Med 2002; 88: 1383-1389.
13.
Platt OS, Brombilla DJ, Rosse WF, et al. Mortality in the sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 336: 1639-1644.
14.
Castro O, Brambilla OJ, Tharington B, et al. The acute chest syndrome in sickle cell disease. Clinical presentation and cause. Cooperative Study of Sickle Cell Disease. Blood 1997; 89: 1787-1792.
15.
Vichinsky EP, Neumayr LD, Eales AN, et al. National Acute Chest Syndrome Study Group. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med 2000; 342(25): 1855-1865.
16.
Wohl S, Quirolo KC. Current issues in blood transfusion for sickle cell disease. Curr Opin Pediatr 2009 Feb; 21(1): 15-21.
17.
Field JJ, De Baun MR. Asthma and sickle cell disease: two distinct diseases or part of the same process.Hematology Am Soc Hematol Educ Program 2009;45-53
18.
Macheda RF, Gladwin MT. Pulmonary hypertension in hemolytic disorders. Chest 2010; 137(6) Suppl: 30S-38S.
19.
Sutton LL, Castro O, Cross DJ, Spencer JE, Levis JF. Pulmonary hypertension in sickle cell disease. Am J Cardiol 1994; 74(6): 626-628.
23